Share on :

Asset Summary

Weekly Performance Report for AMGN ETF: Week 47, 2024

Summary: The Weekly started with AMGN ETF opening at $279.38 and closing at $287.87. The ETF showed resilience throughout the Weekly, with the highest price observed at $288.48 and the lowest at $275.56. The underlying asset had a trading range of $12.92 Overall, it was a positive trading Weekly for AMGN ETF, reflecting investor optimism and market activity.

Change in Closing Price: There was a net increase of $8.49 or 3.04% in the closing price from the opening to the closing price over the Weekly.

Volume Analysis: Trading volume for AMGN ETF was 11,145,563 units during Week 47, indicating active market participation and investor interest.

Opening Price: The Weekly started at $279.38.

Highest Price: The highest price observed during the Weekly was $288.48.

Lowest Price: The lowest price observed during the Weekly was $275.56.

Closing Price: The Weekly ended at $287.87.

Asset Performance Metrics and Risk Characteristics:

Understanding asset performance is crucial for evaluating investment quality and making informed decisions. Metrics like trailing return and drawdown provide insights into how an asset has performed over time, its volatility, and the efficiency of its returns relative to risk. Performance indicators help assess the stability, risk, and reward of an investment, allowing investors and portfolio managers to make comparisons and strategize accordingly.

Asset Technical Analysis

Technical analysis involves evaluating an asset's price and volume data to forecast future movements and make informed trading decisions. By using various technical indicators and chart patterns, investors can gain insights into market trends, price momentum, and potential turning points. This section delves into essential technical metrics, including moving averages, pivot points, and other indicators that provide a snapshot of an asset's current technical stance. Analyzing these indicators helps investors identify entry and exit points, assess market sentiment, and refine their trading strategies. Explore the following technical analysis data to understand the asset's performance dynamics and make better-informed decisions.

Moving Averages

Moving Averages are commonly used to smooth out price data and identify trends over a specific period. Here’s a summary of the latest moving averages for various periods:

  • SMA (Simple Moving Average): Reflects the average price over a specific number of periods.
  • EMA (Exponential Moving Average): Gives more weight to recent prices, making it more responsive to new information.
  • WMA (Weighted Moving Average): Assigns a weight to each price, emphasizing more recent prices.
  • WEMA (Weighted Exponential Moving Average): Combines elements of both WMA and EMA for a more responsive moving average.

Reveal Your AMGN Trading Now

Discover unparalleled trading insights with RankMyTrade.com. Our automated system offers advanced analysis and technical indicators for AMGN, aimed at optimizing your trading decisions. Transform your trading strategy now and get ahead in the market now!

Enhance Your Trading Now

Frequently Asked Questions

Amgen develops innovative medicines that address serious diseases, improving patient outcomes and enhancing the quality of life for patients globally.

Historically, AMGN has shown strong performance and resilience, reflecting the growth trends in the biotechnology sector.

Risks include regulatory challenges, competition from generic drugs, and the volatility associated with biotechnology stocks.

Amgen reports its financial results on a quarterly and annual basis, offering insights into its earnings and business operations.

Amgen is headquartered in Thousand Oaks, California, USA.

Amgen has a history of paying dividends and aims to provide consistent returns to its shareholders while also investing in research and development.

Amgen’s key products include therapies for cancer, kidney disease, rheumatoid arthritis, and other serious medical conditions, such as Neulasta and Enbrel.

Amgen generates revenue primarily through the sale of its biologic drugs and therapies, as well as licensing agreements and partnerships with other companies.

Yes, AMGN can typically be included in retirement accounts such as IRAs or 401(k)s, depending on your brokerage options.

Investing in AMGN may be attractive if you believe in the growth potential of the biotechnology sector, but potential investors should conduct thorough research.

Advance Your AMGN Trading Now

Elevate your trading strategy with RankMyTrade.com’s sophisticated tools for AMGN. Our system integrates cutting-edge technology and expert analysis to support your investment goals. Transform your trading strategy now and explore the benefits of advanced trading now!

Disclaimers

The information displayed on this site is sourced from third-party providers and is believed to be reliable. RankMyTrade (RMT) has not independently verified this data and does not guarantee its accuracy. The information and calculations provided by RankMyTrade are for educational and informational purposes only and should not be construed as financial or investment advice.

With any investment, your capital is at risk. The value of your portfolio go down as well as up. Past performance is no guarantee of future results. By using this website, you accept our Terms of Service, Privacy Policy, and Payment Agreement.

Market data is provided in near real-time when available, but we do not guarantee its accuracy or timeliness.

Securities products are: Not FDIC insured · Not bank guaranteed · May lose value

Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind. Unless otherwise noted, RankMyTrade and its affiliates are not partners, affiliates, or licensees of these companies.

Supported Assets & ETFs